Publications

Publications by Kristine Kleivi Sahlberg

38 publications found

Publications 2019

  1. Johansson HJ, Socciarelli F, Vacanti NM, Haugen MH, Zhu Y, Siavelis I, Fernandez-Woodbridge A, Aure MR, Sennblad B, Vesterlund M, Branca RM, Orre LM, Huss M, Fredlund E, Beraki E, Garred Ø, Boekel J, Sauer T, Zhao W, Nord S, Höglander EK, Jans DC, Brismar H, Haukaas TH, Bathen TF et al. (2019)
    Breast cancer quantitative proteome and proteogenomic landscape
    Nat Commun, 10 (1), 1600
    DOI 10.1038/s41467-019-09018-y, PubMed 30962452
  2. Lindholm EM, Leivonen SK, Undlien E, Nebdal D, Git A, Caldas C, Børresen-Dale AL, Kleivi K (2019)
    miR-342-5p as a Potential Regulator of HER2 Breast Cancer Cell Growth
    Microrna, 8 (2), 155-165
    DOI 10.2174/2211536608666181206124922, PubMed 30520388
  3. Lindholm EM, Ragle Aure M, Haugen MH, Sahlberg KK, Kristensen VN, Nebdal D, Børresen-Dale AL, Lingjaerde OC, Engebraaten O (2019)
    miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer
    Mol Oncol (in press)
    DOI 10.1002/1878-0261.12561, PubMed 31402562

Publications 2018

  1. Tinholt M, Garred Ø, Borgen E, Beraki E, Schlichting E, Kristensen V, Sahlberg KK, Iversen N (2018)
    Subtype-specific clinical and prognostic relevance of tumor-expressed F5 and regulatory F5 variants in breast cancer: the CoCaV study
    J Thromb Haemost, 16 (7), 1347-1356
    DOI 10.1111/jth.14151, PubMed 29766637

Publications 2017

  1. Aure MR, Vitelli V, Jernström S, Kumar S, Krohn M, Due EU, Haukaas TH, Leivonen SK, Vollan HK, Lüders T, Rødland E, Vaske CJ, Zhao W, Møller EK, Nord S, Giskeødegård GF, Bathen TF, Caldas C, Tramm T, Alsner J, Overgaard J, Geisler J, Bukholm IR, Naume B, Schlichting E et al. (2017)
    Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome
    Breast Cancer Res, 19 (1), 44
    DOI 10.1186/s13058-017-0812-y, PubMed 28356166
  2. Cui XY, Skretting G, Tinholt M, Stavik B, Dahm AEA, Sahlberg KK, Kanse S, Iversen N, Sandset PM (2017)
    A novel hypoxia response element regulates oxygen-related repression of tissue factor pathway inhibitor in the breast cancer cell line MCF-7
    Thromb Res, 157, 111-116
    DOI 10.1016/j.thromres.2017.07.013, PubMed 28734156
  3. Fleischer T, Tekpli X, Mathelier A, Wang S, Nebdal D, Dhakal HP, Sahlberg KK, Schlichting E, Oslo Breast Cancer Research Consortium (OSBREAC), Børresen-Dale AL, Borgen E, Naume B, Eskeland R, Frigessi A, Tost J, Hurtado A, Kristensen VN (2017)
    DNA methylation at enhancers identifies distinct breast cancer lineages
    Nat Commun, 8 (1), 1379
    DOI 10.1038/s41467-017-00510-x, PubMed 29123100
  4. Jernström S, Hongisto V, Leivonen SK, Due EU, Tadele DS, Edgren H, Kallioniemi O, Perälä M, Mælandsmo GM, Sahlberg KK (2017)
    Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response
    Breast Cancer (Dove Med Press), 9, 185-198
    DOI 10.2147/BCTT.S115600, PubMed 28356768

Publications 2016

  1. Cui XY, Tinholt M, Stavik B, Dahm AE, Kanse S, Jin Y, Seidl S, Sahlberg KK, Iversen N, Skretting G, Sandset PM (2016)
    Effect of hypoxia on tissue factor pathway inhibitor expression in breast cancer
    J Thromb Haemost, 14 (2), 387-96
    DOI 10.1111/jth.13206, PubMed 26598923
  2. Haukaas TH, Euceda LR, Giskeødegård GF, Lamichhane S, Krohn M, Jernström S, Aure MR, Lingjærde OC, Schlichting E, Garred Ø, Due EU, Mills GB, Sahlberg KK, Børresen-Dale AL, Bathen TF, Oslo Breast Cancer Consortium (OSBREAC) (2016)
    Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes
    Cancer Metab, 4, 12
    DOI 10.1186/s40170-016-0152-x, PubMed 27350877
  3. Nunes-Xavier CE, Karlsen KF, Tekle C, Pedersen C, Øyjord T, Hongisto V, Nesland JM, Tan M, Sahlberg KK, Fodstad Ø (2016)
    Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors
    Oncotarget, 7 (6), 6891-901
    DOI 10.18632/oncotarget.6902, PubMed 26771843
  4. Tinholt M, Sandset PM, Mowinckel MC, Garred Ø, Sahlberg KK, Kristensen VN, Børresen-Dale AL, Jacobsen AF, Skretting G, Iversen N (2016)
    Determinants of acquired activated protein C resistance and D-dimer in breast cancer
    Thromb Res, 145, 78-83
    DOI 10.1016/j.thromres.2016.08.003, PubMed 27505249

Publications 2015

  1. Aure MR, Jernström S, Krohn M, Vollan HK, Due EU, Rødland E, Kåresen R, Oslo Breast Cancer Research Consortium (OSBREAC), Ram P, Lu Y, Mills GB, Sahlberg KK, Børresen-Dale AL, Lingjærde OC, Kristensen VN (2015)
    Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer
    Genome Med, 7 (1), 21
    DOI 10.1186/s13073-015-0135-5, PubMed 25873999
  2. Tinholt M, Vollan HK, Sahlberg KK, Jernström S, Kaveh F, Lingjærde OC, Kåresen R, Sauer T, Kristensen V, Børresen-Dale AL, Sandset PM, Iversen N (2015)
    Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF
    Breast Cancer Res, 17, 44
    DOI 10.1186/s13058-015-0548-5, PubMed 25882602

Publications 2014

  1. Hongisto V, Aure MR, Mäkelä R, Sahlberg KK (2014)
    The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells - A data description
    Genom Data, 2, 249-53
    DOI 10.1016/j.gdata.2014.06.025, PubMed 26484103
  2. Kleivi Sahlberg K, Bottai G, Naume B, Burwinkel B, Calin GA, Børresen-Dale AL, Santarpia L (2014)
    A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients
    Clin Cancer Res, 21 (5), 1207-14
    DOI 10.1158/1078-0432.CCR-14-2011, PubMed 25547678
  3. Nygren MK, Tekle C, Ingebrigtsen VA, Mäkelä R, Krohn M, Aure MR, Nunes-Xavier CE, Perälä M, Tramm T, Alsner J, Overgaard J, Nesland JM, Borgen E, Børresen-Dale AL, Fodstad Ø, Sahlberg KK, Leivonen SK (2014)
    Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c
    Br J Cancer, 110 (8), 2072-80
    DOI 10.1038/bjc.2014.113, PubMed 24577056
  4. Tinholt M, Viken MK, Dahm AE, Vollan HK, Sahlberg KK, Garred O, Børresen-Dale AL, Jacobsen AF, Kristensen V, Bukholm I, Kåresen R, Schlichting E, Skretting G, Lie BA, Sandset PM, Iversen N (2014)
    Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study
    BMC Cancer, 14, 845
    DOI 10.1186/1471-2407-14-845, PubMed 25407022

Publications 2013

  1. Aure MR, Leivonen SK, Fleischer T, Zhu Q, Overgaard J, Alsner J, Tramm T, Louhimo R, Alnæs GI, Perälä M, Busato F, Touleimat N, Tost J, Børresen-Dale AL, Hautaniemi S, Troyanskaya OG, Lingjærde OC, Sahlberg KK, Kristensen VN (2013)
    Individual and combined effects of DNA methylation and copy number alterations on miRNA expression in breast tumors
    Genome Biol, 14 (11), R126
    DOI 10.1186/gb-2013-14-11-r126, PubMed 24257477
  2. Aure MR, Steinfeld I, Baumbusch LO, Liestøl K, Lipson D, Nyberg S, Naume B, Sahlberg KK, Kristensen VN, Børresen-Dale AL, Lingjærde OC, Yakhini Z (2013)
    Identifying in-trans process associated genes in breast cancer by integrated analysis of copy number and expression data
    PLoS One, 8 (1), e53014
    DOI 10.1371/journal.pone.0053014, PubMed 23382830
  3. Hongisto V, Jernström S, Fey V, Mpindi JP, Kleivi Sahlberg K, Kallioniemi O, Perälä M (2013)
    High-throughput 3D screening reveals differences in drug sensitivities between culture models of JIMT1 breast cancer cells
    PLoS One, 8 (10), e77232
    DOI 10.1371/journal.pone.0077232, PubMed 24194875
  4. Leivonen SK, Sahlberg KK, Mäkelä R, Due EU, Kallioniemi O, Børresen-Dale AL, Perälä M (2013)
    High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth
    Mol Oncol, 8 (1), 93-104
    DOI 10.1016/j.molonc.2013.10.001, PubMed 24148764
  5. Tahiri A, Leivonen SK, Lüders T, Steinfeld I, Ragle Aure M, Geisler J, Mäkelä R, Nord S, Riis ML, Yakhini Z, Kleivi Sahlberg K, Børresen-Dale AL, Perälä M, Bukholm IR, Kristensen VN (2013)
    Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors
    Carcinogenesis, 35 (1), 76-85
    DOI 10.1093/carcin/bgt333, PubMed 24104550

Publications 2012

  1. Sahlberg KK, Hongisto V, Edgren H, Mäkelä R, Hellström K, Due EU, Moen Vollan HK, Sahlberg N, Wolf M, Børresen-Dale AL, Perälä M, Kallioniemi O (2012)
    The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells
    Mol Oncol, 7 (3), 392-401
    DOI 10.1016/j.molonc.2012.10.012, PubMed 23253899

Publications 2011

  1. Edgren H, Murumagi A, Kangaspeska S, Nicorici D, Hongisto V, Kleivi K, Rye IH, Nyberg S, Wolf M, Borresen-Dale AL, Kallioniemi O (2011)
    Identification of fusion genes in breast cancer by paired-end RNA-sequencing
    Genome Biol, 12 (1), R6
    DOI 10.1186/gb-2011-12-1-r6, PubMed 21247443
  2. Enerly E, Steinfeld I, Kleivi K, Leivonen SK, Aure MR, Russnes HG, Rønneberg JA, Johnsen H, Navon R, Rødland E, Mäkelä R, Naume B, Perälä M, Kallioniemi O, Kristensen VN, Yakhini Z, Børresen-Dale AL (2011)
    miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors
    PLoS One, 6 (2), e16915
    DOI 10.1371/journal.pone.0016915, PubMed 21364938
  3. Westbury CB, Sahlberg KK, Borresen-Dale AL, Isacke CM, Yarnold JR (2011)
    Gene expression profiling of human dermal fibroblasts exposed to bleomycin sulphate does not differentiate between radiation sensitive and control patients
    Radiat Oncol, 6, 42
    DOI 10.1186/1748-717X-6-42, PubMed 21521514

Publications 2010

  1. Muggerud AA, Hallett M, Johnsen H, Kleivi K, Zhou W, Tahmasebpoor S, Amini RM, Botling J, Børresen-Dale AL, Sørlie T, Wärnberg F (2010)
    Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer
    Mol Oncol, 4 (4), 357-68
    DOI 10.1016/j.molonc.2010.06.007, PubMed 20663721
  2. Rantala JK, Edgren H, Lehtinen L, Wolf M, Kleivi K, Vollan HK, Aaltola AR, Laasola P, Kilpinen S, Saviranta P, Iljin K, Kallioniemi O (2010)
    Integrative functional genomics analysis of sustained polyploidy phenotypes in breast cancer cells identifies an oncogenic profile for GINS2
    Neoplasia, 12 (11), 877-88
    DOI 10.1593/neo.10548, PubMed 21082043

Publications 2009

  1. Leivonen SK, Mäkelä R, Ostling P, Kohonen P, Haapa-Paananen S, Kleivi K, Enerly E, Aakula A, Hellström K, Sahlberg N, Kristensen VN, Børresen-Dale AL, Saviranta P, Perälä M, Kallioniemi O (2009)
    Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines
    Oncogene, 28 (44), 3926-36
    DOI 10.1038/onc.2009.241, PubMed 19684618
  2. Muggerud AA, Edgren H, Wolf M, Kleivi K, Dejeux E, Tost J, Sørlie T, Kallioniemi O (2009)
    Data integration from two microarray platforms identifies bi-allelic genetic inactivation of RIC8A in a breast cancer cell line
    BMC Med Genomics, 2, 26
    DOI 10.1186/1755-8794-2-26, PubMed 19432969

Publications 2007

  1. Kleivi K, Lind GE, Diep CB, Meling GI, Brandal LT, Nesland JM, Myklebost O, Rognum TO, Giercksky KE, Skotheim RI, Lothe RA (2007)
    Gene expression profiles of primary colorectal carcinomas, liver metastases, and carcinomatoses
    Mol Cancer, 6, 2
    DOI 10.1186/1476-4598-6-2, PubMed 17201907

Publications 2006

  1. Diep CB, Kleivi K, Ribeiro FR, Teixeira MR, Lindgjaerde OC, Lothe RA (2006)
    The order of genetic events associated with colorectal cancer progression inferred from meta-analysis of copy number changes
    Genes Chromosomes Cancer, 45 (1), 31-41
    DOI 10.1002/gcc.20261, PubMed 16145679
  2. Kleivi K (2006)
    Advances in the genetics and epigenetics of gene regulation and human disease
    Genome Biol, 7 (8), 325
    DOI 10.1186/gb-2006-7-8-325, PubMed 16934107
  3. Lind GE, Kleivi K, Meling GI, Teixeira MR, Thiis-Evensen E, Rognum TO, Lothe RA (2006)
    ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis
    Cell Oncol, 28 (5-6), 259-72
    PubMed 17167179

Publications 2005

  1. Kleivi K, Diep CB, Pandis N, Heim S, Teixeira MR, Lothe RA (2005)
    TP53 mutations are associated with a particular pattern of genomic imbalances in breast carcinomas
    J Pathol, 207 (1), 14-9
    DOI 10.1002/path.1812, PubMed 16007576

Publications 2004

  1. Kleivi K, Teixeira MR, Eknaes M, Diep CB, Jakobsen KS, Hamelin R, Lothe RA (2004)
    Genome signatures of colon carcinoma cell lines
    Cancer Genet Cytogenet, 155 (2), 119-31
    DOI 10.1016/j.cancergencyto.2004.03.014, PubMed 15571797

Publications 2002

  1. Kleivi K, Lothe RA, Heim S, Tsarouha H, Kraggerud SM, Pandis N, Papadopoulou A, Andersen J, Jakobsen KS, Teixeira MR (2002)
    Genome profiling of breast cancer cells selected against in vitro shows copy number changes
    Genes Chromosomes Cancer, 33 (3), 304-9
    DOI 10.1002/gcc.10032, PubMed 11807988